- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07619898
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure (PHOENIX-ECP)
PHOENIX- A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis or Hepatitis With Inadequate Response to Corticosteroids in Participants With Unresectable or Metastatic Melanoma Treated With Immune Checkpoint Inhibitors (ICI)
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light.
Immune checkpoint inhibitor therapy is widely used for the treatment of several cancers, including melanoma. However, a common immune-related adverse event associated with this therapy is Immune-related colitis or hepatitis. Corticosteroids are typically the first-line treatment for this condition, but some participants do not respond adequately.
The purpose of this study is to evaluate the efficacy of ECP in the treatment of immune-related (ir)-colitis and ir-hepatitis with inadequate response to corticosteroids, and to compare its efficacy to other second-line immunosuppressant therapies. The ECP procedure in this study is performed using the CELLEX® device, a fully closed-loop extracorporeal blood circulation device. The CELLEX device is used in conjunction with methoxsalen.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Therakos TKS2001 Study Team
- Número de teléfono: 855-512-3327
- Correo electrónico: Clinicaltrials@therakos.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Participants diagnosed with unresectable or metastatic melanoma ( Stage III and Stage IV) received ICI treatment (e.g., anti-PD-1, anti-PD-L1, anti-LAG-3, anti-CTLA-4 antibody, as ICI monotherapy or ICI combination therapy) and ICI paused or discontinued because of the development of ir-colitis or ir-hepatitis.
- Participants diagnosed with ir-colitis and/or ir-hepatitis with a severity of Grade 2 or higher, based on ASCO Guidelines (
- Participants with endoscopic evidence of ir-colitis
- Participants with inadequate response to corticosteroids, as defined per protocol
- Participants who have Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
Exclusion Criteria:
- Presence of irAEs in addition to and other than ir-colitis and/or ir-hepatitis, with a higher severity grade than the irAE for inclusion (ir-colitis/ir-hepatitis) based on ASCO guidelines.
- Participant has a diagnosis of uveal melanoma as the sole melanoma subtype
- Treatment of ir-colitis or ir-hepatitis with any systemic therapy other than corticosteroids
- Concurrent conditions which may require treatment with high dose corticosteroid (> 1 milligram per kilogram per day [mg/kg/day]) and interfere with the corticosteroid tapering schedule recommended by the protocol.
- Pre-existing liver disease
- Active alcohol use disorder
- Concomitant treatment with any chemotherapy or targeted therapy for the treatment of unresectable or metastatic melanoma.
- Use of any investigational agent within 5 half-lives of the investigational agent prior to randomization.
- Contraindications or known allergic reaction to any of study intervention and/or procedures
- Participants unable to tolerate the fluid shift associated with the ECP procedure.
- Positive result for active or previous viral infections: covid-19, hepatitis B/C, CMV, EBV, adenovirus
- History of previous or concurrent malignancies within the last 3 years, other than unresectable or metastatic melanoma.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Methoxsalen in Conjunction with Extracorporeal Photopheresis System (ECP)
Participants will receive methoxsalen, in conjunction with ECP
|
Sterile solution used in conjunction with CELLEX ECP
Otros nombres:
Methoxsalen is used in conjunction with the CELLEX ECP
Otros nombres:
|
|
Comparador activo: Best Available Therapy (BAT)
Participants with ir-colitis will receive either Infliximab or Vedolizumab as per the investigator's choice.
Participants with ir-hepatitis will receive Mycophenolate Mofetil (MMF) or Azathioprine as per the investigator's choice.
|
Vedolizumab will be administered intravenously
Infliximab will be administered intravenously
Mycophenolate Mofetil will be administered orally or intravenously
Azathioprine will be administered orally or intravenously
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Proportion of Participants Who are in Steroid-free response at Week 12 for the Randomized Immune-related Adverse Event (irAE) (ir-colitis or ir-hepatitis)
Periodo de tiempo: Week 12
|
Week 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Duration of irAE response
Periodo de tiempo: Week 64
|
Time from the start of irAE response to either the relapse of irAE (if relapse occurs), or a censoring event.
|
Week 64
|
|
Progression Free Survival (PFS) for Melanoma
Periodo de tiempo: Week 64
|
Week 64
|
|
|
Overall Survival (OS)
Periodo de tiempo: Week 64
|
Week 64
|
|
|
Proportion of Participants With at Least Stable Disease as Assessed by RECIST 1.1 at Week 12 and During Follow-up
Periodo de tiempo: Week 12 and Week 64
|
Week 12 and Week 64
|
|
|
Proportion of Participants with Treatment-Emergent Adverse Event (TEAEs) per Common Toxicity Criteria for Adverse Events (CTCAE) v5.0
Periodo de tiempo: From first dose of the study drug up to end of study (up to Week 64)
|
From first dose of the study drug up to end of study (up to Week 64)
|
|
|
Cumulative Systemic Corticosteroid Exposure From Randomization to Week 12
Periodo de tiempo: Up to Week 12
|
Up to Week 12
|
|
|
Peak Dose of Systemic Corticosteroid Exposure From Randomization to Week 12
Periodo de tiempo: Up to Week 12
|
Up to Week 12
|
|
|
Proportion of Participants who Completely Discontinue Systemic Corticosteroid Treatment Until Week 12
Periodo de tiempo: Week 12
|
Week 12
|
|
|
Time to Complete Discontinuation of Systemic Corticosteroids for at Least 1 Week
Periodo de tiempo: From screening up to the first documentation of the discontinuation of systemic corticosteroid (up to Week 64)
|
From screening up to the first documentation of the discontinuation of systemic corticosteroid (up to Week 64)
|
|
|
Time to First Response of Randomized irAE Based on ASCO Criteria
Periodo de tiempo: Week 64
|
Week 64
|
|
|
Proportion of Participants With at Least one irAE who Achieve Response (as Defined per ASCO Criteria) at Week 12
Periodo de tiempo: Week 12
|
Week 12
|
|
|
Proportion of Participants With at Least One irAE That Resolves Completely (as per CTCAE v5.0) and Remains Resolved Until Week 12
Periodo de tiempo: Week 12
|
Week 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Isabelle T Seemann, Ph.D, Therakos LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Ensayo controlado aleatorizado
- Melanoma
- Dispositivo
- Melanoma metastásico
- Melanoma irresecable
- PAE
- Colitis
- Eventos adversos relacionados con la inmunidad
- Colitis relacionada con el sistema inmunitario
- Ensayo clínico de fase 2
- Fotoféresis extracorpórea
- Metoxsaleno
- Refractario de esteroides
- Immune checkpoint inhibitor toxicity
- Checkpoint inhibitor-induced colitis
- Checkpoint inhibitor-induced hepatitis
- Immune checkpoint Inhibitors
- UVADEX
- Corticosteroid refractory
- Cellex
- 8-Mop
- Ir-AE
- Ir-AE Colitis
- Ir-AE Hepatitis
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades intestinales
- Neoplasias por tipo histológico
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del HIGADO
- Enfermedades del Colon
- Enfermedades de la piel
- Gastroenteritis
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Neoplasias De La Piel
- Enfermedades de la piel y del tejido conectivo
- Hepatitis
- Colitis
- Melanoma
- Aminoácidos, péptidos y proteínas
- Proteínas
- Compuestos de azufre
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Terapéutica
- Piranos
- Ácidos grasos
- Lípidos
- Procedimientos quirúrgicos, operativo
- Ácidos nucleicos, nucleótidos y nucleósidos
- Ácidos, acíclico
- Ácidos carboxílicos
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Purinas
- Nucleósidos
- Cumarinas
- Benzopirans
- Caproates
- Fototerapia
- Compuestos heterocíclicos, 3 anillos
- Circulación extracorpórea
- Terapia Puva
- Terapia ultravioleta
- Furocoumarinas
- Tionucleósidos
- Mercaptopurina
- Infliximab
- Ácido micofenólico
- Azatioprina
- Metoxsaleno
- vedolizumab
- Fotoféresis
Otros números de identificación del estudio
- TKS2001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .